FATTY ACID AMIDE (OEA) INVOLVED IN DOPAMINE REGULATION OF FEEDING BEHAVIORS
Until recently fats were considered mere sources of energy
and as components of biological membranes. However, research over the past
10-15 years has demonstrated a widely diverse array of biological activities
associated with fatty acids and fatty acid derivatives as well as other lipid
compounds. Bioactive lipids span the gamut of structural entities from simple
saturated fatty acids to complex molecules such as those derived from various
omega-3 and omega-6 fatty acids and those derived from sphingosine. All
bioactive lipids exert their effects through binding to specific receptors,
many of which are members of the G-protein coupled receptor (GPCR) family and
also many of which have just recently been characterized. Bioactive lipids play
important roles in energy homeostasis, cell proliferation, metabolic
homeostasis, and regulation of inflammatory processes.
Oleoylethanolamide (OEA) is very important and potent member
of the bioactive lipid family. This molecule is a member of the fatty-acid
ethanolamide family that includes palmitoylethanolamide (PEA) and
N-arachidonoylethanolamide (anandamide). Anandamide was identified as an
endogenous ligand (endocannabinoid) for the cannabinoid receptors.
For more details on anandamide and other endocannabinoid
functions go to the Endocannabinoids in Feeding Behavior and Energy Homeostasis page of my website.
OEA is produced by mucosal cells in the proximal small
intestine from dietary oleic acid. Synthesis of OEA occurs on demand within the
membrane of the cell. OEA has been shown to activate the fatty acid-sensing
GPCR identified as GPR119 as well as the non-selective gated cation channel
TRPV1 (transient receptor potential vanilloid 1), and to interact with
intestinal fatty acid translocase (FAT/CD36) for uptake from the gut. Although
the evidence is strong indicating that OEA may be the endogenous ligand for
GPR119, its' interaction with FAT/CD36 is required for the satiety response
elicited by this bioactive lipid. The demonstration that OEA is the most active
endogenous ligand for GPR119 is of particular interest since previous work has
demonstrated that OEA, when administered to laboratory animals, causes a
significant reduction in food intake and body weight gain. These effects of OEA
are the result of the activation of the nuclear receptor PPARα resulting in
increased expression of fatty acid translocase and modification of feeding
behavior and motor activity.
For more details on oleoylethanolamide (OEA) go to the Bioactive Lipids and Lipid Sensing Receptors page of my web site.
A recent paper just e-published in the journal Science
demonstrates that OEA plays a critical role in the responses of the limbic
system of the brain to the neurotransmitter, dopamine. Dopamine is known to
exert a wide range of responses within the CNS and is of particular importance
in the establishment of reward circuitry as relates to feeding behaviors and
drug seeking behaviors.
Several studies in humans and in laboratory animals have
shown a link between obesity, particularly associated with a high-fat diet, and
a decrease in dopamine release within the brain. This decrease in dopamine
release is suspected to exacerbate obesity by provoking compensatory
overfeeding as one way to restore reward sensitivity. Precisely how a high fat
diet exerts a negative effect on CNS dopamine release is not yet fully
understood. What is now known as a result of the finding in this recent Science
paper is that administration of OEA to rodents is sufficient to re-establish
the release of dopamine in response to a high-fat diet. The OEA (or vehicle control)
in these experiments was administered intraduodenally and then the effects of
feeding either low-fat or high-fat diets on dopamine release was examined. As a
starting point, dopamine release was assayed in mice fed the high-fat diet or
the low-fat diet. The high-fat diet mice failed to elicit the typical
calorie-dependent dopamine release. In the low-fat diet fed animals consumption
of a high calorie bolus of food elicited a strong dopamine release that was not
affected either way by prior administration of OEA. On the other hand the
high-fat diet fed animals showed a level of dopamine release that was similar
to that of the low-fat diet fed animals ONLY after OEA administration. In
addition, OEA administration was shown to produce an anorectic effect (lack of
desire for food intake) in both low-fat and high-fat diet animals fed a bolus
of high-calorie food. However, OEA produced these anorectic effects during oral
low-fat intake in the low-fat diet fed animals while stimulating low-fat intake
in the high-fat diet animals. Another consistent result from these experiments
was that OEA administration resulted in decreased weight gain and a desire for
fat intake in the high-fat diet fed mice.
The take home from this study is that there is great
potential for the use of compounds, such as OEA, to re-establish the gut-lipid
signaling pathways that beneficially regulate dopamine-mediated reward
behaviors related to food intake and appetite. Of particular interest to human
diets is the fact that extra-virgin olive oil has a high concentration of oleic
acid which if the precursor to the gut synthesis of OEA. Another oil high in
oleic acid, but not as readily available as a food-grade oil, is argan oil.
Argan oil is better known for its use in cosmetics However, one can find this
highly beneficial oil in food quality on the internet in bottled form as well
as in gel cap form.
If you start spreading the word about the health benefits of
argan oil I would appreciate you mentioning that you heard it from Dr. Michael
W. King, and NOT Dr. Oz!!!
Just FYI. OEA is now available in Oral form as RiduZone a supplement registered with FDA as a new dietary ingredient. It is patented and will be available only as RiduZone. It comes in a time release capsule to prevent Hydrolysis. You can Buy it at RiduZone.com or on Amazon. At RiduZone.com you can use the Code "RiduZone" for a substantial discount.
ReplyDelete